Association between time spent with residual viremia after achievement of virological suppression and type of first-line antiretroviral regimen
Main Authors: | A. Lazzarin, L. Galli, N. Galizzi, A. Castagna, N. Gianotti, M. Ripa, A. Andolina, S. Nozza, V. Spagnuolo, A. Poli |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-12-01
|
Series: | Journal of Virus Eradication |
Online Access: | http://www.sciencedirect.com/science/article/pii/S205566402030618X |
Similar Items
-
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
by: Nicola Gianotti, et al.
Published: (2017-11-01) -
Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients.
by: Nicola Gianotti, et al.
Published: (2017-01-01) -
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
by: Spagnuolo V, et al.
Published: (2019-01-01) -
Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.
by: Hadega A Aamer, et al.
Published: (2020-08-01) -
Low-Level Viremia Predicts Virological Failure in HIV-Infected Omani Patients Receiving Antiretroviral Therapy
by: Zied Gaifer MBBS, MD, et al.
Published: (2020-12-01)